Inhibition of inhaled metabisulphite-induced bronchoconstriction by inhaled frusemide and ipratropium bromide.
1. The effect of inhaled frusemide and high dose inhaled ipratropium bromide on bronchoconstriction induced by inhaled metabisulphite was studied in 10 atopic volunteers. 2. Frusemide (40 mg), ipratropium bromide (0.5 mg) or saline placebo were administered by nebuliser in a double-blind fashion, prior to construction of a dose-response curve to metabisulphite (2.5-100 mg ml-1). 3. Geometric mean of the provocative dose of metabisulphite that caused a 35% fall in specific airways resistance (sGaw) after placebo was 13 (95% confidence intervals CI 4-36 mumol) compared with 36 (16-78) mumol after ipratropium bromide and 45 (22-94) mumol after frusemide. 4. Mean maximum fall in sGaw was 49 (40-57)% after placebo, 11 (0-22)% after frusemide and -1 (-25-22)% after ipratropium bromide. 5. Frusemide significantly protected against metabisulphite induced bronchoconstriction (P less than 0.005). The protection from high dose ipratropium bromide was also significant (P less than 0.05), but the response was more variable between subjects.
Bellingan
G J
GJ
Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London.
Dixon
C M
CM
Ind
P W
PW
D000280:Administration, Inhalation; D000328:Adult; D016084:Bronchoconstriction / Q000187:drug effects*; D004311:Double-Blind Method; D005260:Female; D005665:Furosemide / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D009241:Ipratropium / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D011897:Random Allocation; D013447:Sulfites / Q000008:administration & dosage / Q000037:antagonists & inhibitors*
D013447:Sulfites; C030981:metabisulfite; D005665:Furosemide; D009241:Ipratropium